# Pluri Inc.: financial statements, quarterly

PLUR · Nasdaq · CIK 1158780 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/plur.md) · [Financials](/companies/plur/financials.md) · [Filings](/companies/plur/filings.md) · [Insiders](/companies/plur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/plur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [54.0](/filings/0001213900-24-096763.md) | [105](/filings/0001213900-25-012189.md) | [71.0](/filings/0001213900-25-042637.md) | [96.0 d](/filings/0001213900-25-088578.md) | [326](/filings/0001213900-25-109174.md) | [185](/filings/0001213900-26-015550.md) | [427](/filings/0001213900-26-056586.md) | [398 d](/filings/0001213900-26-098862.md) | [316](/filings/0001213900-25-109174.md) | [198](/filings/0001213900-26-015550.md) | [167](/filings/0001213900-26-056586.md) | [335 d](/filings/0001213900-26-098862.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | [126](/filings/0001213900-25-109174.md) | [74.0](/filings/0001213900-26-015550.md) | [291](/filings/0001213900-26-056586.md) | [191 d](/filings/0001213900-26-098862.md) | [201](/filings/0001213900-25-109174.md) | [112](/filings/0001213900-26-015550.md) | [111](/filings/0001213900-26-056586.md) | [139 d](/filings/0001213900-26-098862.md) |
| Gross profit | $k | [54.0](/filings/0001213900-24-096763.md) | [105](/filings/0001213900-25-012189.md) | [71.0](/filings/0001213900-25-042637.md) | [92.0 d](/filings/0001213900-25-088578.md) | [200](/filings/0001213900-25-109174.md) | [111](/filings/0001213900-26-015550.md) | [136](/filings/0001213900-26-056586.md) | [207 d](/filings/0001213900-26-098862.md) | [115](/filings/0001213900-25-109174.md) | [86.0](/filings/0001213900-26-015550.md) | [56.0](/filings/0001213900-26-056586.md) | [196 d](/filings/0001213900-26-098862.md) |
| Research and development | $k | [2,993](/filings/0001213900-24-096763.md) | [2,964](/filings/0001213900-25-012189.md) | [3,094](/filings/0001213900-25-042637.md) | [3,395 d](/filings/0001213900-25-088578.md) | [2,889](/filings/0001213900-25-109174.md) | [2,925](/filings/0001213900-26-015550.md) | [3,043](/filings/0001213900-26-056586.md) | [3,994 d](/filings/0001213900-26-098862.md) | [3,931](/filings/0001213900-25-109174.md) | [3,826](/filings/0001213900-26-015550.md) | [3,962](/filings/0001213900-26-056586.md) | [3,373 d](/filings/0001213900-26-098862.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(5,377)](/filings/0001213900-24-096763.md) | [(5,213)](/filings/0001213900-25-012189.md) | [(5,534)](/filings/0001213900-25-042637.md) | [(6,034) d](/filings/0001213900-25-088578.md) | [(5,198)](/filings/0001213900-25-109174.md) | [(4,957)](/filings/0001213900-26-015550.md) | [(5,400)](/filings/0001213900-26-056586.md) | [(6,621) d](/filings/0001213900-26-098862.md) | [(6,350)](/filings/0001213900-25-109174.md) | [(6,506)](/filings/0001213900-26-015550.md) | [(6,536)](/filings/0001213900-26-056586.md) | [(5,546) d](/filings/0001213900-26-098862.md) |
| Interest expense | $k | [214](/filings/0001213900-23-086065.md) | [216](/filings/0001213900-24-012549.md) | [218](/filings/0001213900-24-041274.md) | [218 d](/filings/0001213900-25-088578.md) | [217](/filings/0001213900-25-109174.md) | [211](/filings/0001213900-26-015550.md) | [212](/filings/0001213900-26-056586.md) | [233 d](/filings/0001213900-26-098862.md) | [229](/filings/0001213900-25-109174.md) | [231](/filings/0001213900-26-015550.md) | [237](/filings/0001213900-26-056586.md) | [235 d](/filings/0001213900-26-098862.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(8.0)](/filings/0001213900-25-109174.md) | [(8.0)](/filings/0001213900-26-015550.md) | [(8.0)](/filings/0001213900-26-056586.md) | [(1.0) d](/filings/0001213900-26-098862.md) |
| Net income | $k | [(4,961)](/filings/0001213900-24-096763.md) | [(4,905)](/filings/0001213900-25-012189.md) | [(5,293)](/filings/0001213900-25-042637.md) | [(5,729) d](/filings/0001213900-25-088578.md) | [(5,882)](/filings/0001213900-25-109174.md) | [(2,956)](/filings/0001213900-26-015550.md) | [(6,147)](/filings/0001213900-26-056586.md) | [(7,598) d](/filings/0001213900-26-098862.md) | [(5,850)](/filings/0001213900-25-109174.md) | [(6,543)](/filings/0001213900-26-015550.md) | [(5,548)](/filings/0001213900-26-056586.md) | [(5,880) d](/filings/0001213900-26-098862.md) |
| Diluted EPS | $ per share | [(0.96)](/filings/0001213900-24-096763.md) | [(0.96)](/filings/0001213900-25-012189.md) | [(1.01)](/filings/0001213900-25-042637.md) | not reported | [(1.08)](/filings/0001213900-25-109174.md) | [(0.53)](/filings/0001213900-26-015550.md) | [(0.94)](/filings/0001213900-26-056586.md) | not reported | [(0.65)](/filings/0001213900-25-109174.md) | [(0.71)](/filings/0001213900-26-015550.md) | [(0.55)](/filings/0001213900-26-056586.md) | not reported |
| Basic EPS | $ per share | [(0.96)](/filings/0001213900-24-096763.md) | [(0.96)](/filings/0001213900-25-012189.md) | [(1.01)](/filings/0001213900-25-042637.md) | not reported | [(1.08)](/filings/0001213900-25-109174.md) | [(0.53)](/filings/0001213900-26-015550.md) | [(0.94)](/filings/0001213900-26-056586.md) | not reported | [(0.65)](/filings/0001213900-25-109174.md) | [(0.71)](/filings/0001213900-26-015550.md) | [(0.55)](/filings/0001213900-26-056586.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.3](/filings/0001213900-24-096763.md) | [5.5](/filings/0001213900-24-012549.md) | [7.1](/filings/0001213900-24-041274.md) | [6.8](/filings/0001213900-25-088578.md) | [3.2](/filings/0001213900-24-096763.md) | [7.2](/filings/0001213900-25-012189.md) | [8.5](/filings/0001213900-25-042637.md) | [5.9](/filings/0001213900-26-098862.md) | [4.3](/filings/0001213900-25-109174.md) | [4.7](/filings/0001213900-26-015550.md) | [3.4](/filings/0001213900-26-056586.md) | [3.5](/filings/0001213900-26-098862.md) |
| Current assets | $m | [35.3](/filings/0001213900-23-086065.md) | [32.3](/filings/0001213900-24-012549.md) | [27.4](/filings/0001213900-24-041274.md) | [31.1](/filings/0001213900-25-088578.md) | [27.0](/filings/0001213900-24-096763.md) | [22.4](/filings/0001213900-25-012189.md) | [27.5](/filings/0001213900-25-042637.md) | [22.1](/filings/0001213900-26-098862.md) | [16.9](/filings/0001213900-25-109174.md) | [13.8](/filings/0001213900-26-015550.md) | [10.5](/filings/0001213900-26-056586.md) | [8.7](/filings/0001213900-26-098862.md) |
| Total assets | $m | [44.5](/filings/0001213900-23-086065.md) | [41.6](/filings/0001213900-24-012549.md) | [36.4](/filings/0001213900-24-041274.md) | [39.5](/filings/0001213900-25-088578.md) | [35.4](/filings/0001213900-24-096763.md) | [30.9](/filings/0001213900-25-012189.md) | [37.4](/filings/0001213900-25-042637.md) | [38.7](/filings/0001213900-26-098862.md) | [33.7](/filings/0001213900-25-109174.md) | [30.6](/filings/0001213900-26-015550.md) | [26.1](/filings/0001213900-26-056586.md) | [24.9](/filings/0001213900-26-098862.md) |
| Current liabilities | $m | [4.3](/filings/0001213900-23-086065.md) | [4.5](/filings/0001213900-24-012549.md) | [4.5](/filings/0001213900-24-041274.md) | [4.5](/filings/0001213900-25-088578.md) | [4.6](/filings/0001213900-24-096763.md) | [4.4](/filings/0001213900-25-012189.md) | [5.7](/filings/0001213900-25-042637.md) | [32.3](/filings/0001213900-26-098862.md) | [32.2](/filings/0001213900-25-109174.md) | [32.3](/filings/0001213900-26-015550.md) | [32.0](/filings/0001213900-26-056586.md) | [32.7](/filings/0001213900-26-098862.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [8.9](/filings/0001213900-23-086065.md) | [4.4](/filings/0001213900-24-012549.md) | [(0.4)](/filings/0001213900-24-041274.md) | [0.1](/filings/0001213900-25-088578.md) | [(5.3)](/filings/0001213900-24-096763.md) | [(8.0)](/filings/0001213900-25-012189.md) | [(4.5)](/filings/0001213900-25-042637.md) | [(6.8)](/filings/0001213900-26-098862.md) | [(11.4)](/filings/0001213900-25-109174.md) | [(14.6)](/filings/0001213900-26-015550.md) | [(18.6)](/filings/0001213900-26-056586.md) | [(23.0)](/filings/0001213900-26-098862.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,857)](/filings/0001213900-24-096763.md) | [(3,649) d](/filings/0001213900-25-012189.md) | [(4,202) d](/filings/0001213900-25-042637.md) | [(4,313) d](/filings/0001213900-25-088578.md) | [(4,064)](/filings/0001213900-25-109174.md) | [(4,628) d](/filings/0001213900-26-015550.md) | [(4,303) d](/filings/0001213900-26-056586.md) | [(5,216) d](/filings/0001213900-26-098862.md) | [(5,428)](/filings/0001213900-25-109174.md) | [(5,205) d](/filings/0001213900-26-015550.md) | [(4,512) d](/filings/0001213900-26-056586.md) | [(4,443) d](/filings/0001213900-26-098862.md) |
| Capital expenditure | $k | [103](/filings/0001213900-24-096763.md) | [121 d](/filings/0001213900-25-012189.md) | [89.0 d](/filings/0001213900-25-042637.md) | [10.0 d](/filings/0001213900-25-088578.md) | [208](/filings/0001213900-25-109174.md) | [112 d](/filings/0001213900-26-015550.md) | [577 d](/filings/0001213900-26-056586.md) | [721 d](/filings/0001213900-26-098862.md) | [116](/filings/0001213900-25-109174.md) | [447 d](/filings/0001213900-26-015550.md) | [44.0 d](/filings/0001213900-26-056586.md) | [26.0 d](/filings/0001213900-26-098862.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.6](/filings/0001213900-23-086065.md) | [33.2](/filings/0001213900-24-012549.md) | [5.0](/filings/0001213900-24-041274.md) | [5.2](/filings/0001213900-24-096763.md) | [5.2](/filings/0001213900-25-012189.md) | [5.2](/filings/0001213900-25-042637.md) | [5.5](/filings/0001213900-25-109174.md) | [5.6](/filings/0001213900-26-015550.md) | [6.6](/filings/0001213900-26-056586.md) | [9.0](/filings/0001213900-25-109174.md) | [9.3](/filings/0001213900-26-015550.md) | [10.1](/filings/0001213900-26-056586.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,344,736 at 2026-09-09, from the cover of the [10-K filed 2026-09-10](/filings/0001213900-26-098862.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.